KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Deferred Revenue (2016 - 2025)

Novavax (NVAX) has 16 years of Current Deferred Revenue data on record, last reported at $500.0 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 25.93% year-over-year to $500.0 million; the TTM value through Dec 2025 reached $500.0 million, down 25.93%, while the annual FY2025 figure was $500.0 million, 25.93% down from the prior year.
  • Current Deferred Revenue reached $500.0 million in Q4 2025 per NVAX's latest filing, up from $104.3 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.6 billion in Q4 2021 and bottomed at $28.0 million in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $921.8 million, with a median of $885.5 million recorded in 2023.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 26331.38% in 2021, then plummeted 97.41% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.6 billion in 2021, then crashed by 65.56% to $549.6 million in 2022, then surged by 57.13% to $863.5 million in 2023, then fell by 21.82% to $675.1 million in 2024, then decreased by 25.93% to $500.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $500.0 million in Q4 2025, $104.3 million in Q3 2025, and $513.0 million in Q2 2025.